The consequences for human health of recent breakthroughs in fundamental biology -including the landmark sequencing of the human genome -are impossible to predict with any certainty.
However, the biomedical community appears confident that unprecedented advances in our ability to prevent, detect, and treat disease are within reach. If so, there will be striking improvements in population health, and, if one believes the most optimistic forecasts, a concomitant decrease in the total resources devoted to medical care.
This optimism must be tempered by some pressing demographic trends. The number of Americans 65 years or older is projected to double by 2030. And the past few decades have witnessed alarming increases in obesity and diabetes among the young. 1 Disability rates for the young have risen within all demographic and economic groups. The volume and intensity of health services are also rising rapidly. 2 All of these trends could significantly increase health care spending. 3 This paper considers how new medical advances will affect health and health care delivery for the elderly. The type of innovation is important, and we consider several. Those that prevent disease -heart disease, diabetes, cancer and Alzheimer's are potentially the most promising -could protect large portions of the population and forestall expensive complications. Better treatments for existing disease might also be developed drawing on advances in gene therapy and bioengineering. But medical technology alone will not determine future outcomes; demographics and health trends also play a key role. So we also consider the implications for spending as successive cohorts age into Medicare. Next we describe the model we use to simulate future health and spending.
MODEL OF ELDERLY HEALTH AND SPENDING
We developed a demographic and economic model to predict clinically warranted, and age. We treated all health conditions as "absorbing" -i.e., once people got an illness, they had it forever and therefore could not get it again -and modeled transitions into these conditions. This assumption was consistent with the way the data were obtained ("Has a doctor ever told you…") and with the course of most chronic diseases.
Based on these hazard models, we then predicted each person's probability of dying, getting a new disease, or entering a new functional state using Monte Carlo techniques.
As our initial sample ages, it becomes less representative of the Medicare population. We annually replenish our sample through 2030 with a new cohort of 65-year-olds using data on the health of younger cohorts from the 1982 to 1996 National Health Interview Surveys to predict the health of new Medicare entrants. For example, the health of 65-year olds in 2026 will depend on the health of 35-year olds in 1996, appropriately trended. We then used this model to simulate the consequences of recent health trends.
CONSEQUENCES OF RECENT HEALTH TRENDS
The health of the elderly has been improving in important ways since the early 1980s. 5 However, the rising prevalence of diseases like obesity and diabetes among the young and increases in disability suggest that future cohorts entering into Medicare may be less healthy. 1, 6 The net effect of these trends is unclear. Improvements in health will allow the elderly to live longer and accrue more expenses and, as it is sometimes argued, ultimately incur more health care costs. The issue is further complicated because the effects depend in large measure on the mix of disease and disability, since not all conditions are equally expensive to treat over a lifetime.
We used our model to untangle these effects in three scenarios of the health of future entrants into Medicare. The first scenario, which is our preferred estimate, forecasts the constellation of disease taking into account all the information at our disposal, especially the health of the younger cohorts observed in the National Health Interview Study (Scenario A).
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The second assumes that the entering cohorts will have a 
Intraventricular cardioverter defibrillators (ICD).
These devices can be implanted in the heart to continuously monitor the heart rhythm and apply a therapeutic shock when life-threatening arrhythmias are detected. This simulation greatly expands this technology to primary prevention: 50% of patients with either heart failure or a myocardial infarction would receive a surgical implantation at a onetime cost of $37,500 (1999 dollars). We assumed no annual maintenance costs; this generous assumption is partially offset by the not allowing the cost of implants to decline over time, as one might expect with a mature technology.
Patients with an ICD are assumed to have a 10% lower mortality rate.
Left ventricular assist devices (LVAD).
These devices, similar to "artificial hearts," are implanted into the chest to aid the left ventricle of the heart in pumping blood. This is a technology traditionally used as a bridge to heart transplantation; we model improvements to allow permanent implantation. About 10% of patients with heart failure would receive an implant at a cost of $120,000 and with subsequent mortality improvement of 15%. As with ICDs, we assume no maintenance costs as a partial offset to no decline in the device cost over time.
3. Pacemakers to control atrial fibrillation. Atrial fibrillation is a disturbance of the heart rhythm that is common in older persons and contributes to both heart failure and stroke. The therapy -similar to taking bevacizumab for colorectal cancer -would cost $4,800 per month. We assume patients get the treatment for one year initially. At that time, 30% of patients are determined to be responsive and continue to receive the treatment for four more years.
Therapy is assumed to be perfectly effective for these patients; that is, it shrinks the tumor to such a small size that the patient is effectively cured. The remaining 70% are non-responsive and go off the treatment. Other technologies achieve health improvements at a very high price. These include anti-angiogenesis, pacemakers for atrial fibrillation, and left ventricular assist devices. All of these are very expensive in relation to the health benefits they are known to produce. Our findings for anti-angiogenensis are consistent with recent experience with bevacizumab (trade name Avastin), an anti-angiogenesis drug used to treat patients with advanced colorectal cancer. This drug extends median survival by about 5 months at a treatment cost of $50,000 or more. 13 Our simulations show that if treatment is broadened, the cost per additional life year could go even higher. Without clear criteria for who will respond to anti-angiogenesis, and how long they will need to remain on these drugs, costs per additional life year are likely to be very high.
Telomerase inhibitors has the potential to save money to offset its treatment costs; treatment is forecasted to cost $6.4
billion by 2030 but total health care expenditures will rise very modestly (0.5%). These savings occur because people are dying of less expensive diseases. If the cost of the treatment could be reduced, it therefore could be very cost-effective.
Attempts to prevent both diabetes and Alzheimer's disease are not forecast to be cost-effective, in part this is because they involve treatment of large fractions of the population, and the efficacy is limited. Better risk stratification in the future will allow for better targeting; however, these screening tests will also likely be very expensive initially. We also do not include any potential savings to families alleviated of the burden of illness, which can be very high with some diseases. Under the less optimistic scenario that the pill keeps people alive but increases disease and disability, the consequences are enormous. Total health care spending in 2030 would be 70% higher than under the status quo, since there would be more elderly and people would incur disease and disability at older ages. Still, this treatment is relatively inexpensive -$30,000 per additional life-year. This scenario shows the inherent tension in medical improvements generally -we can keep people alive to incur more disease and disability, but the overall rate is one that many consider "worth it."
Simulations of this sort require certain caveats. First, we do not adjust our estimates -as many actuarial models doto reflect historical trends in real health care costs.
Including such projections would not change our conclusions about the relative impact of new innovations.
14 Furthermore, our goal is to isolate the effects of new technologies, whereas historical trends subsume some level of technological improvement. Thus, we would in some sense be "double counting"
if we added a new technology on top of the trended projections.
More generally, changes in behavior are beyond the scope of our model, which is meant to highlight the effects of incremental improvements in medical technology. So, for example, our estimates of the effects of a drug that might improve longevity can be taken only as starting point for discussion. Such a technology is so transforming that it is well-beyond the capacity of such a model to deal with it. As life-expectancy moves beyond 100 years, people might take better care of themselves (or perhaps decide to "live-it-up"), work longer, and behave in fundamentally different ways. Society as a whole will be transformed. Our goal in presenting this scenario in particular is merely to demonstrate the technological risk embodied by current biomedical research-and consider its implications as best we can.
In addition, the ultimate effect of a technology depends on its timing and its price, both of which are difficult to forecast, are interrelated, and influence diffusion. But it is unclear how to forecast future prices in the context of our model. The panels recognized, but could not predict, that costs of a procedure will fall over time with higher rates of adoption. We assumed these technologies were similar to treatments they resemble or replace.
Finally, it should be noted that we focus on the elderly.
Of course, access to technology will not be restricted to older
Americans. Many of the new treatments will be expensive and hence will raise the cost of health insurance for the nonelderly, and fewer people will be able to afford comprehensive coverage. With fragmented health insurance markets and incomplete health insurance coverage, the fruits of medical progress will be distributed unevenly. Furthermore, the benefits that any socioeconomic group derives from innovations will depend on the prevalence of treatable disease in that group. If we design cures for the diseases of "rich people" -as cardiovascular disease once was -then gradients in health are likely to widen. (1) Based on self-report; conditions are permanent ("ever had") (2) Mutually exclusive; "ADL" refers to difficulty performing or inability to perform one of six activities: bathing or showering, dressing, eating, getting in or out of bed or chairs, walking, using the toilet. 
Notes for Exhibits 3 and 4:
The Figures show forecasts of disability prevalence and health care costs under three scenarios based on data from the Medicare Current Beneficiary Survey and the National Health Interview Study. Scenario A, our preferred scenario, incorporates health status information for younger cohorts, including information on prevalence of disability and major chronic conditions. Scenario B ignores this information and assumes that entrants to Medicare resemble recent entrants. Scenario C assumes that disability is falling among all the elderly based on trends from the 1990's. Notes: All spending is in constant (1999) dollars. The exhibit shows the treatment costs, additional health care expenditures, and cost per additional life-year associated with 10 promising medical innovations. Treatment costs refer to the costs of providing the listed breakthrough and are based on comparisons with existing technologies as identified by expert panels. The additional health care expenditures differ from treatment costs because the breakthroughs can lead to changes in disability, morbidity and mortality, all of which are accounted for in the simulation model. Costs per additional life year do not include improvements in morbidity and disability during a lifetime and hence should be thought of as upper bounds on a cost-effectiveness ratio.
The simulations are based on data from the Medicare Current Beneficiary Survey and the National Health Interview Study.
